Skip to main content
. 2020 Apr 21;34(6):651–659. doi: 10.1007/s40263-020-00730-8

Table 1.

Patient characteristics of benzodiazepines (BZDs) and pharmaceutical gamma-hydroxybutyric acid (GHB) detoxification groups

BZD (n = 42) Pharmaceutical GHB (n = 42) p
Male: n (%) 29 (69.0%) 31 (73.8%) 0.801
Age: years (SD) 30.5 (5.5) 28.7 (5.6) 0.130
Months of daily GHB use (SD) 44.8 (46.4) 51.1 (33.4) 0.493
Daily ml GHB (SD) 76.7 (61.9) 75.7 (52.4) 0.953
Co-morbid substance use (in past thirty days)
 Nicotine 92.3% 94.2% 0.702
 Alcohol 76.0% 59.1% 0.090
 Stimulants 55.6% 60.4% 0.637

SD standard deviation